Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes
Top Cited Papers
- 1 September 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine & Science in Sports & Exercise
- Vol. 46 (9), 1744-1751
- https://doi.org/10.1249/mss.0000000000000297
Abstract
The START was a Canadian multicenter trial that randomized 242 breast cancer patients between 2003 and 2005 to usual care (n = 82), supervised aerobic (n = 78), or resistance (n = 82) exercise during chemotherapy. The primary end point for this exploratory analysis was disease-free survival (DFS). Secondary end points were overall survival, distant DFS, and recurrence-free interval. The two exercise arms were combined for analysis (n = 160), and selected subgroups were explored. After a median follow-up of 89 months, there were 25/160 (15.6%) DFS events in the exercise groups and 18/82 (22.0%) in the control group. Eight-year DFS was 82.7% for the exercise groups compared with 75.6% for the control group (HR, 0.68; 95% confidence interval (CI), 0.37–1.24; log-rank, P = 0.21). Slightly stronger effects were observed for overall survival (HR, 0.60; 95% CI, 0.27–1.33; log-rank, P = 0.21), distant DFS (HR, 0.62; 95% CI, 0.32–1.19; log-rank, P = 0.15), and recurrence-free interval (HR, 0.58; 95% CI, 0.30–1.11; Gray test, P = 0.095). Subgroup analyses suggested potentially stronger exercise effects on DFS for women who were overweight/obese (HR, 0.59; 95% CI, 0.27–1.27), had stage II/III cancer (HR, 0.61; 95% CI, 0.31–1.20), estrogen receptor-positive tumors (HR, 0.58; 95% CI, 0.26–1.29), human epidermal growth factor receptor 2-positive tumors (HR, 0.21; 95% CI, 0.04–1.02), received taxane-based chemotherapies (HR, 0.46; 95% CI, 0.19–1.15), and ≥85% of their planned chemotherapy (HR, 0.50; 95% CI, 0.25–1.01). This exploratory follow-up of the START provides the first randomized data to suggest that adding exercise to standard chemotherapy may improve breast cancer outcomes. A definitive phase III trial is warranted.Keywords
This publication has 24 references indexed in Scilit:
- Reducing breast cancer recurrence with weight loss, a vanguard trial: The Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) TrialContemporary Clinical Trials, 2013
- Physical Activity, Biomarkers, and Disease Outcomes in Cancer Survivors: A Systematic ReviewJNCI Journal of the National Cancer Institute, 2012
- The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials GroupCurrent Oncology, 2008
- Influence of a Diet Very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for Breast CancerJAMA, 2007
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition StudyJNCI Journal of the National Cancer Institute, 2006
- Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: A randomized controlled trialBrain, Behavior, and Immunity, 2005
- Changes in Body Fat and Weight After a Breast Cancer Diagnosis: Influence of Demographic, Prognostic, and Lifestyle FactorsJournal of Clinical Oncology, 2005
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Influence of Exercise on the Pharmacokinetics of DrugsClinical Pharmacokinetics, 1990